Status:
UNKNOWN
Development of an Algorithm to Better Predict Clinical Responsiveness to Peanut
Lead Sponsor:
Hamilton Health Sciences Corporation
Collaborating Sponsors:
Food Allergy Initiative
AllerGen NCE Inc.
Conditions:
Peanut Hypersensitivity
Eligibility:
All Genders
5+ years
Brief Summary
The purpose of this study is to develop a tool to better predict clinical allergy to peanut, so that those who are skin test positive but non allergic will not have to unnecessarily avoid peanut, and ...
Detailed Description
Peanut allergy occurs in about 1% of the population. Allergic reactions to peanuts and tree nuts account for the majority of fatal and near fatal food allergic reactions. Currently the only available ...
Eligibility Criteria
Inclusion
- 5 years of age and older
- Informed consent (Subject has provided an appropriately signed and dated informed consent. An appropriately signed and dated assent must be obtained from the parents or guardian if the subject is a child under 18 years of age.)
- Free of any clinically significant disease, such as uncontrolled asthma, which may interfere with study evaluations
- Group 1:
- skin test positive to peanut
- documented clinical history of peanut allergy. A documented clinical history may include symptoms such as hives,swelling of the mouth or tongue, throat closing sensation, shortness of breath, wheezing, lightheadedness, anaphylaxis.
- Group 2:
- Positive skin test to peanut
- History of being able to tolerate peanut exposure without problems
- Group 3:
- Positive skin test to peanut
- No known ingestion of peanut
- Group 4:
- Negative skin test to peanut
- Negative skin test to other food and environmental allergens
- Able to tolerate peanut exposure without problems
Exclusion
- Women who are pregnant or nursing
- use of antihistamines or decongestant therapy four days prior to clinic visit
- use of nasal or inhaled corticosteroid in the 1 month period prior to clinic visit
- use of non-steroidal anti-inflammatory drugs (NSAIDS) in the week prior to clinic visit
- Moderate or severe/ uncontrolled asthma (defined as the use of more than 4 puffs of ventolin per day, not including prophylactic medications prior to exercise)
- Symptomatic allergic rhinitis
- Patients who had an acute allergic reaction to food, drugs, and bee sting in the 1 month period prior to clinic visit
- Use of an epi-pen during the past month
- respiratory infection one month prior to clinic visit
- immunotherapy
Key Trial Info
Start Date :
September 1 2002
Trial Type :
OBSERVATIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00243555
Start Date
September 1 2002
Last Update
February 1 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton Health Sciences Corporation, McMaster Site
Hamilton, Ontario, Canada, L8N 3Z5